Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5(TM) Topical Gel
July 25, 2017 07:55 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jul 25, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today...
Arch Therapeutics Presents Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017
June 06, 2017 12:25 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jun 6, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today...
Arch Therapeutics to Provide Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017
May 22, 2017 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - May 22, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be...
Arch Therapeutics to Provide Corporate Update at the 29th Annual Roth Conference on Monday, March 13, 2017
March 06, 2017 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Mar 6, 2017) - Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and...
Arch Therapeutics to Provide Corporate Update at the Maxim Group - Haitong Securities Healthcare Investor and Partnering Conference
February 27, 2017 08:18 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Feb 27, 2017) - Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic...
Arch Therapeutics, Inc. $6.1 Million Registered Direct Offering
February 21, 2017 09:08 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Feb 21, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a developer of innovative materials as hemostatic and wound care devices, today...
Arch Therapeutics Provides Corporate Milestone Update, Including Anticipated Filing of 510(k) for AC5(TM)
February 16, 2017 11:05 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Feb 16, 2017) - Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH), developer of innovative materials as hemostatic and wound care devices,...
Arch Therapeutics to Provide Corporate Updates at Two Conferences in New York, February 2017
February 08, 2017 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Feb 8, 2017) - Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and...
Arch Therapeutics Announces Issuance of Method-of-Use Patent Covering Self-Assembling Peptidomimetics
February 02, 2017 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Feb 2, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, announced...
Arch Therapeutics to Present at Noble Financial Capital Markets' Thirteenth Annual Equity Conference
January 23, 2017 09:44 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jan 23, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5™ devices for use in...